Janssen funds cancer study using Vital Connect, physIQ tech
Mobi Health News
JULY 17, 2018
Vital Connect and physIQ are teaming up with the Haga Teaching Hospital in the Netherlands to conduct a study on how wearable biosensors and artificial intelligence can augment care for cancer patients undergoing treatment. Specifically, the study — which is funded by Johnson & Johnson subsidiary Janssen Pharmaceuticals — is looking to see how the technology can detect adverse events in cancer treatment early on.
Let's personalize your content